The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development
- PMID: 11051546
- DOI: 10.1016/s0092-8674(00)00103-3
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development
Abstract
Osteoprotegerin-ligand (OPGL) is a key osteoclast differentiation/activation factor essential for bone remodeling. We report that mice lacking OPGL or its receptor RANK fail to form lobulo-alveolar mammary structures during pregnancy, resulting in death of newborns. Transplantation and OPGL-rescue experiments in opgl-/- and rank-/- pregnant females showed that OPGL acts directly on RANK-expressing mammary epithelial cells. The effects of OPGL are autonomous to epithelial cells. The mammary gland defect in female opgl-/- mice is characterized by enhanced apoptosis and failures in proliferation and PKB activation in lobulo-alveolar buds that can be reversed by recombinant OPGL treatment. These data provide a novel paradigm in mammary gland development and an evolutionary rationale for hormonal regulation and gender bias of osteoporosis in females.
Similar articles
-
IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development.Cell. 2001 Dec 14;107(6):763-75. doi: 10.1016/s0092-8674(01)00599-2. Cell. 2001. PMID: 11747812
-
Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.Am J Pathol. 2000 Mar;156(3):761-7. doi: 10.1016/s0002-9440(10)64942-5. Am J Pathol. 2000. PMID: 10702390 Free PMC article.
-
A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response.J Biol Chem. 2004 Jul 16;279(29):30202-9. doi: 10.1074/jbc.M403968200. Epub 2004 May 15. J Biol Chem. 2004. PMID: 15145935
-
Molecular control of bone remodeling and osteoporosis.Exp Gerontol. 2000 Oct;35(8):947-56. doi: 10.1016/s0531-5565(00)00178-9. Exp Gerontol. 2000. PMID: 11121682 Review.
-
Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.Eur J Endocrinol. 1999 Sep;141(3):195-210. doi: 10.1530/eje.0.1410195. Eur J Endocrinol. 1999. PMID: 10474114 Review. No abstract available.
Cited by
-
Skeletal and extraskeletal actions of denosumab.Endocrine. 2012 Aug;42(1):52-62. doi: 10.1007/s12020-012-9696-x. Epub 2012 May 13. Endocrine. 2012. PMID: 22581255 Review.
-
A case of minimal change disease after the administration of anti receptor activator of nuclear factor kappa B ligand (RANKL) monoclonal antibody: a case report.BMC Nephrol. 2020 Sep 29;21(1):416. doi: 10.1186/s12882-020-02066-3. BMC Nephrol. 2020. PMID: 32993539 Free PMC article.
-
Evaluation of rs3102735 and rs2073617 Osteoprotegerin Gene Polymorphisms and the Risk of Childhood Acute lymphoblastic Leukemia in Zahedan Southeast Iran.Int J Hematol Oncol Stem Cell Res. 2014 Oct 1;8(4):39-44. Int J Hematol Oncol Stem Cell Res. 2014. PMID: 25774266 Free PMC article.
-
Genetic polymorphism of the OPG gene associated with breast cancer.BMC Cancer. 2013 Jan 31;13:40. doi: 10.1186/1471-2407-13-40. BMC Cancer. 2013. PMID: 23369128 Free PMC article.
-
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.Nat Rev Drug Discov. 2012 May;11(5):401-19. doi: 10.1038/nrd3705. Nat Rev Drug Discov. 2012. PMID: 22543469 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous